CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Reardon, exercised 5,000 stock options and immediately sold the resulting common shares for a transaction value of approximately $1.03 million, as disclosed in a SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value $1.0 million Post-transaction shares (direct) Post-transaction value (direct ownership) ~$7.70 million Transaction value based on SEC Form 4 weighted average purchase price ($206.35); post-transaction value based on March 4, 2026 market close ($206.35). Key questions How does the size of this transaction compare to Reardon's recent historical sell activity? This 5,000-share sale is materially larger than Reardon's median sell transaction of 750 shares during the recent period (February 2025 to March 2026), and exceeds the typical 1.73% of holdings per sale observed in that timeframe. Did the transaction have a lasting impact on Reardon's equity exposure to Ligand Pharmaceuticals? While direct common stock ho
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]Yahoo! Finance
- Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes [Yahoo! Finance]Yahoo! Finance
- Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know [Yahoo! Finance]Yahoo! Finance
- Ligand Advances Strategic Growth with Expanded and Strengthened Business Development TeamGlobeNewswire
- Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/1/26 - Form 144
- LGND's page on the SEC website